Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Manufacturer/Factory, Trading Company
Gold Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Registered Capital
5000000 RMB
Plant Area
101~500 square meters
  • Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
  • Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
  • Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
  • Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
  • Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
Find Similar Products

Basic Info.

Model NO.
500mg
Suitable for
Elderly, Children, Adult
State
Solid
Shape
Tablet
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Transport Package
Carton
Specification
500mg
Trademark
Voice-Bio
Origin
China
HS Code
2933290090
Production Capacity
10000000

Product Description


Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mgMetronidazole Tablets 500mg
Specification 100 tablets/ box
Shelf life 3Years
Storage Shade, airtight, store in a cool place below 30ºC

Therapeutic indications
Symptomatic Trichomoniasis.
Metronidazole tablets are indicated for the treatment of T. vaginalisinfection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).

Asymptomatic Trichomoniasis.
Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalisinfection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.

Treatment of Asymptomatic Sexual Partners. 
T. vaginalisinfection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection.

Amebiasis.
Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.
In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus.

Anaerobic Bacterial Infections.
Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets.

Dose and method of administration
Trichomoniasis:
In the Female:
One-day treatment− two grams of metronidazole tablets, given either as a single dose or in two divided doses of one gram each, given in the same day.

Seven-day course of treatment- 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.
The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.
Pregnant patients should not be treated during the first trimester. In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation.
When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.
In the Male: Treatment should be individualized as it is for the female.

Amebiasis
Adults:
For acute intestinal amebiasis (acute amebic dysentery):750 mg orally three times daily for 5 to 10 days.

For amebic liver abscess:500 mg or 750 mg orally three times daily for 5 to 10 days.
Pediatric patients:35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.

Anaerobic Bacterial Infections
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially.
The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.
The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.

Contraindications
Hypersensitivity
Metronidazole tablets are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives.
In patients with trichomoniasis, metronidazole tablets are contraindicated during the first trimester of pregnancy.
Psychotic Reaction with Disulfiram
Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer metronidazole to patients who have taken disulfiram within the last two weeks.
Interaction with Alcohol
Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole.
Cockayne Syndrome
Metronidazole Tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with Cockayne syndrome.

Special warnings and precautions for use
Hepatic Impairment
Patients with hepatic impairment metabolize metronidazole slowly, with resultant accumulation of metronidazole in the plasma. For patients with severe hepatic impairment (Child-Pugh C), a reduced dose of metronidazole is recommended. For patients with mild to moderate hepatic impairment, no dosage adjustment is needed but these patients should be monitored for metronidazole associated adverse events.
Renal Impairment
Patients with end-stage renal disease may excrete metronidazole and metabolites slowly in the urine, resulting in significant accumulation of metronidazole metabolites. Monitoring for metronidazole associated adverse events is recommended.
Fungal Superinfections
Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with a candidacidal agent.
Use in Patients with Blood Dyscrasias
Metronidazole is a nitroimidazole and should be used with caution in patients with evidence of or history of blood dyscrasia. A mild leukopenia has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy.
Drug-Resistant Bacteria and Parasites
Prescribing metronidazole in the absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria and parasites.

Interaction with other medicinal products and other forms of interaction
Disulfiram
Psychotic reactions have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks.
Alcoholic Beverages
Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy.
Warfarin and other Oral Anticoagulants
Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When metronidazole is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored.
Lithium
In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication.

Fertility, pregnancy and lactation
Not suitable for pregnant and lactating women.

PHARMACOLOGICAL PROPERTIES
This product is a nitroimidazole derivative, which can inhibit the redox reaction of amoeba and break the nitrogen chain of protozoa. Metronidazole has a killing effect on anaerobic microorganisms. The metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial DNA, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. Carcinogenic to some animals.

Packaging & Shipping
Comercial Packing 100's/Box or Customized
Production Time About 30-60days after artwork confirmed

Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mgCertifications
Business License, Manufacturing License, Certificate of Pharmaceutical Products (CoPP), Free Sales Certificate (FSC), and technical documents for registration.
 
Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
Since 2015, NINGBO VOICE BIOCHEMIC CO. LTD. is a professional company to offer one-package service for FPP (Finished Pharmaceutical Products ); APIs (Active Pharmaceutical Ingredients); (Pharmaceutical Intermediates ); Veterinary Pharmaceuticals.that meet of Standard GMP and current BP,USP version.
 

Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mgWholesale Pharmaceutical Medicine Metronidazole Tablets 500mg
Wholesale Pharmaceutical Medicine Metronidazole Tablets 500mgOur Service
1.Mixed container, we can mix different items in one container.
2.Free professional and creative artwork design.
3.OEM service.
4.Registration documents supported.
5.Packing as your request, with photo before shipment.


We will spare no efforts to meet your demands!
 please feel free to contact us 
 
Address:   298 West Zhongshan Road, Ningbo, P.R. China 
Attn: Mr. Medic  Ren  
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier